Apomorphine and ropinirole data sharpen emetic choice in dogs

A growing body of evidence is sharpening the choice between apomorphine and ropinirole when dogs need emesis induced in-clinic. A 2025 Frontiers in Veterinary Science crossover study in 24 healthy dogs found both agents were highly effective, with success rates of 95.8% for IV apomorphine and 100% for ophthalmic ropinirole, but apomorphine worked faster, with a median onset of 1.18 minutes versus 8.85 minutes for ropinirole. A separate 2025 Journal of Veterinary Emergency and Critical Care trial in 132 client-owned dogs presenting after suspected toxin or foreign-body ingestion adds more real-world context: dogs were randomized at two referral hospitals to ropinirole eye drops (63) or IV apomorphine (69), with a second dose allowed if no vomiting occurred within 20 minutes and monitoring through 40 minutes. That emergency study reached a less favorable conclusion for ropinirole, reporting lower first-dose success, slower onset, more minor adverse effects, and more prolonged vomiting requiring rescue therapy. That adds nuance to a category changed in 2020 by FDA approval of Clevor, the first FDA-approved drug to induce vomiting in dogs, giving practices a labeled ophthalmic alternative to the long-familiar, extra-label use of apomorphine. (public-pages-files-2025.frontiersin.org)

Why it matters: For veterinary teams, the decision is no longer just about whether an emetic works, but which tradeoffs fit the patient, the toxin, and the workflow. Apomorphine still appears to offer the fastest onset, which may matter in time-sensitive toxicology cases, but it is extra-label in the U.S., can worsen CNS depression, and may require more careful handling. Ropinirole offers a labeled, unit-dose ophthalmic option that may be easier to administer and less likely to add to CNS depressant effects, but it should be avoided in dogs with underlying ocular disease and may bring more ocular redness or prolonged vomiting in some settings. In the emergency trial, enrolled dogs covered the kinds of cases clinicians actually see, including toxic foods, plants, medications, rodenticides, and foreign material such as toys, cords, and clothing, underscoring that performance may differ from healthy-dog research conditions. (vetmed.illinois.edu)

What to watch: Watch for whether future clinical studies in real-world toxicology and foreign-body cases confirm ropinirole as a true practice-changing alternative, or reinforce apomorphine’s edge in speed and reliability for emergency use. Also worth watching on the supportive-care side: Dechra says its newly approved maropitant injectable, Emeprev, a bioequivalent antiemetic for dogs and cats expected through distributors in early 2026, is designed to reduce injection pain and simplify storage, which could matter when prolonged vomiting after emesis induction requires rescue treatment. (pubmed.ncbi.nlm.nih.gov)